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The formation, distribution, and maintenance of functional mitochondria are achieved through dynamic processes that
depend strictly on the transcription of nuclear genes encoding mitochondrial proteins. A large number of these mitochon-
drial genes contain binding sites for the transcription factor Yin Yang 1 (YY1) in their proximal promoters, but the physio-
logical relevance is unknown. We report here that skeletal-muscle-specific YY1 knockout (YY1mKO) mice have severely
defective mitochondrial morphology and oxidative function associated with exercise intolerance, signs of mitochondrial
myopathy, and short stature. Gene set enrichment analysis (GSEA) revealed that the top pathways downregulated in
YY1mKO mice were assigned to key metabolic and regulatory mitochondrial genes. This analysis was consistent with a
profound decrease in the level of mitochondrial proteins and oxidative phosphorylation (OXPHOS) bioenergetic function
in these mice. In contrast to the finding for wild-type mice, inactivation of the mammalian target of rapamycin (mTOR)
did not suppress mitochondrial genes in YY1mKO mice. Mechanistically, mTOR-dependent phosphorylation of YY1 re-
sulted in a strong interaction between YY1 and the transcriptional coactivator peroxisome proliferator-activated receptor
gamma coactivator 1 (PGC1), a major regulator of mitochondrial function. These results underscore the important role
of YY1 in the maintenance of mitochondrial function and explain how its inactivation might contribute to exercise intoler-
ance and mitochondrial myopathies.
Mitochondrial organelles are dynamic tubular or roundedstructures in the cytoplasm largely devoted to nutrient me-
tabolism and bioenergetics. The size, integrity, and location of
mitochondria are controlled through different protein-regulated
processes that depend on timely, adequate transcriptional control
of nuclear genes encoding mitochondrial proteins (16, 18, 20, 25,
29, 35). These mitochondrial processes are regulated in response
to different bioenergetic demands to maintain cellular energy ho-
meostasis. At the tissue level, proper mitochondrial function is
essential for adaptation to different physiological conditions, for
example, to energetic demands in skeletal muscle during exercise
(9, 23). Notably, dysregulation of mitochondrial processes is as-
sociated with a broad array of diseases, including myopathies and
neurodegeneration, underscoring the importance of intact mito-
chondrial activities in human health (8, 41).
Mitochondrial structural and functional processes depend
strictly on a continuous, regulated supply of mitochondrial pro-
teins, initially provided by the activities of transcriptional compo-
nents bound to the promoters of nuclear mitochondrial genes.
Twodifferent families of transcription factors play a pivotal role in
the control ofmitochondrial genes: the nuclear respiratory factors
(NRF1 and NRF2) and the nuclear hormone estrogen-related re-
ceptors (ERR, ERR, and ERR) (11, 28). Interestingly, the ac-
tivity of these transcriptional factors is strongly amplified by the
expression of the peroxisome proliferator-activated receptor
gamma coactivator 1 (PGC1) family of coactivators, which in-
cludes PGC1, PGC1, and PRC (12, 14, 34). The assembly of
these transcription factors and PGC1 coactivators ensures the ro-
bust induction of a full program of gene expression necessary for
all facets of mitochondrial function: biogenesis, cellular distribu-
tion, and bioenergetic activity. For example, tissue-specific trans-
genic expression of PGC1 in skeletal muscle is sufficient to fully
convertmuscle fibers from type 2 fast-twitch to type 1 slow-twitch
fibers with high mitochondrial content (22). Furthermore,
PGC1 transgenic mice are largely protected against several mi-
tochondrial myopathies and age-associated diseases (43, 44).
Using computational genomics, we determined previously
that a large number of nuclear mitochondrial genes activated by
PGC1 contained DNA binding sites for the transcription factor
YY1 (10). YY1 binds DNA through four C-terminal zinc finger
domains and can function as an activator or repressor of gene
expression (31, 49). Within the context of mitochondrial genes,
YY1 physically interacts with and recruits PGC1 to target pro-
moters. From a regulatory standpoint, the interaction between
these two proteins is dependent onmammalian target of rapamy-
cin (mTOR) activity, but the molecular mechanisms accounting
for this interaction are unknown. Interestingly, mTOR controls
mitochondrial gene expression, and a deficiency of mTOR or the
mTOR complex 1 (mTORC1) component raptor in skeletal mus-
cle-specific knockout (KO) mice results in a profound mitochon-
drial dysregulation associated with dystrophy (4, 32). These
mouse phenotypes are exactly the opposites of those described
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above for the skeletal muscle PGC1 transgenic mice and support
convergence of this signaling/transcriptional pathway.Despite the
fact that YY1 was placed in this pathway, the precise role of YY1 in
skeletal muscle mitochondrial physiology in vivo and the way in
which it impacts physiopathology at the tissue and whole-body
levels are unknown.
We report here that specific YY1 deficiency in skeletal mus-
cle results in profound mitochondrial dysregulation, exercise
intolerance, and signs of myopathy causing attenuated postna-
tal growth and short stature. Skeletal-muscle-specific YY1
knockout (YY1mKO) mice contained a decreased number of
mitochondria with severe morphological defects, including
poorly formed cristae and accumulation of intramitochondrial
aggregates. Moreover, mitochondria were disorganized and
mislocalized in the myofiber architectural structure. This phe-
notype was consistent with a strong decrease in mitochondrial
gene expression that resulted in bioenergetic deficiencies. In-
terestingly, YY1mKO mice were insensitive to the suppressive
effects of the mTOR inhibitor rapamycin on mitochondrial
genes. Molecularly, mTOR-dependent phosphorylation of YY1
led to interaction with PGC1 and increased mitochondrial
gene expression. These results support an important functional
role of YY1 in maintaining skeletal muscle mitochondrial mor-
phology and bioenergetic state, and they indicate that YY1 in-
activation results in a phenotype that resembles mitochondrial
diseases.
MATERIALS AND METHODS
Constructs and reagents. YY1 and YY1 short hairpin RNA (shRNA) ad-
enoviral constructs have been described previously (10). YY1 site-directed
mutations were made using QuikChange site-directed mutagenesis
(Stratagene). The antibodies used were anti-YY1 (Santa Cruz catalog no.
281), anti-PGC1 (Santa Cruz catalog no. 13067), antitubulin (Upstate
catalog no. 05-661), antiporin (Mitoscience catalog no. MSA03), anti-
succinate dehydrogenase complex, subunit A (anti-SDHA; Mitoscience
catalog no. MS204), anti-ATPase  (Mitoscience catalog no. MS502),
anti-Core II (Mitoscience catalog no. MS304), anti-Ndufa9 (Mitoscience
catalog no. MS111), anti-Ndufs3 (Mitoscience catalog no. MS110), and
anti-Cox5a (Mitoscience catalog no. MS409).
Generation of YY1mKO mice. YY1mKO mice were generated by
breeding animals harboring a floxed YY1 allele (1) with mice that trans-
genically express cis-acting replication element (CRE) recombinase under
the control of the myogenin promoter and the MEF2C enhancer (19).
Wild-type littermates carrying the floxed allele but not CRE were used as
a control group. These mice have a mixed background.
Animal experiments. All experiments and protocols were approved
by the Institutional Animal Care and Use Committee of the Dana-Farber
Cancer Institute or Beth Israel Deaconess Medical Center. Mice were
housed on a 12-h:12-h light-dark cycle (lights on at 6 a.m.). Mice were
allowed ad libitum access to standard laboratory rodent chow. The fat and
lean tissue masses in living, nonanesthetized mice were determined by
using magnetic resonance imaging (MRI) equipment (EchoMedical Sys-
tems, Houston, TX). Six-week-old YY1mKO males and wild-type litter-
mates were injected daily intraperitoneally at 5 p.m. with 2.5 mg/kg of
body weight rapamycin or a vehicle (0.1% dimethyl sulfoxide [DMSO] in
sterile phosphate-buffered saline [PBS]).Micewith free access to food and
water were sacrificed 12 h after final rapamycin/vehicle injection (5 a.m.).
Twelve-week-old raptor knockout (RamKO) males and wild-type litter-
mates were injected daily intraperitoneally at 5 p.m. with 2.5 mg/kg rapa-
mycin or a vehicle (0.1% DMSO in sterile PBS). Mice with free access to
food andwater were sacrificed 12 h after final rapamycin/vehicle injection
(5 a.m.).
Exercise performance. Six-month-oldmice were run on amotorized,
speed-controlled, modular treadmill system (Columbus Instruments).
The treadmill was equipped with an electric shock stimulus. Mice were
acclimatized to the treadmill for a week (10min/day); then either themice
were time/distance run to exhaustion or the number of stops within 10
min was recorded. For the experiment to exhaustion, mice were run at 5
m/min for 5 min, and then the speed was increased every 5 min up to 20
m/min (in 5-m/min steps). For the stop count, they were run at 10m/min
for 10 min, and then the number of falls into the motivational grid was
counted for an additional 10 min. For voluntary exercises, mice were
housed individually in cages containing a running wheel (Bio-Serv,
Frenchtown, NJ) for 6 days, and their running activity was monitored.
Histology and EM. For electron microscopy (EM) analyses, adult
mice were euthanized, and muscle tissue was rapidly fixed with Kar-
novsky’s fixative (2% glutaraldehyde, 1% paraformaldehyde, and 0.08%
sodium cacodylate). Muscle was dissected, postfixed in 1% osmium te-
troxide, dehydrated in graded ethanol, embedded in Poly-Bed plastic
resin, and sectioned for EM. EM was performed by the Harvard Medical
School Electron Microscopy core facility. For hematoxylin and eosin
(H&E) staining, mice were euthanized and were rapidly fixed in Bouin’s
fixative. Muscle tissue was formalin fixed, embedded in paraffin, sec-
tioned, and stained with H&E and Masson’s trichrome. For SDH, cyto-
chrome oxidase (COX), and periodic acid-Schiff stain (PAS) staining,
muscle tissue was frozen in isopentane that had been cooled in liquid
nitrogen. Staining was performed by the Specialized Histopathology Ser-
vice using standard protocols for these assays (Longwood, Boston, MA).
Cell culture and treatments. C2C12 cells were cultured in Dulbecco’s
modified Eagle medium (DMEM) containing 10% fetal bovine serum.
C2C12 myoblasts were differentiated in DMEM with 2% horse serum for
72 h before infection with the indicated adenoviral constructs. Forty-
eight- to 72-h-infected C2C12myotubes were treated with 20 nM rapamy-
cin or a vehicle for 16 h.
Gene expression analysis. RNA was isolated by TRIzol (Invitrogen),
reverse transcribed using SuperScript II reverse transcriptase, and ana-
lyzed by quantitative real-time PCR (qRT-PCR)with SYBR green fluores-
cence. Primer sequences are available upon request. Cell culture data were
normalized to-actin expression.Mouse data were normalized to 2-beta-
mercaptoethanol (2-M) expression, and RNA was extracted from the
skeletal muscles of fed mice. A list of qRT-PCR primer sequences is pro-
vided in Fig. S5 in the supplemental material.
ChIP.Cells were fixed in 1% formaldehyde–serum-free DMEM for 10
min at 37°C. Cross-linking was then quenched in 0.150 M glycine, and
cells were washed twice in PBS. Cells were collected in chromatin immu-
noprecipitation (ChIP) buffer (50 mM HEPES, 140 mM NaCl, 1 mM
EDTA, 1% Triton, 0.1% sodium deoxycholate [NaDOC], 0.1% sodium
dodecyl sulfate [SDS] with fresh protease inhibitors). Samples were son-
icated 6 times with a duty cycle of 30 s on/30 s off, and 10 g of DNA was
immunoprecipitated (16 h) with either 2 g of YY1 antibody (sc-281;
Santa Cruz) or IgG. Immunocomplexes were recovered with protein A
Dynabeads (100-02D; Invitrogen) and were washed 6 times. DNA was
de-cross-linked, purified, and then quantified by qPCR. Mice (n  4)
were first treated with a vehicle or with 2.5 mg/kg rapamycin for 2 weeks,
then fasted for 16 h, and finally refed for 6 h before sacrifice. Two gastroc-
nemius muscles of each mouse were dissected, cut in pieces, and fixed in
1% formaldehyde-PBS for 15 min at room temperature. The fixation was
quenched by adding a final concentration of 0.150 M glycine, and muscle
pieces were washed twice in cold PBS. The tissuewas homogenized in cold
PBS (containing protease inhibitors) in a motor pestle. The homogenate
was filtered in 100-m-pore-size cell strainers and was pelleted by cen-
trifugation for 5min at 4,000 rpm and 4°C. The pellet was resuspended in
500 l SDS lysis buffer from the Millipore EZ-ChIP kit. Samples were
sonicated in aDiagenodeBioruptor for 5 duty cycles of 30 s on/30 s off and
were finally centrifuged for 15 min at 10,000 g. Fifty microliters of each
sample was diluted 1:10 in dilution buffer (from the EZ-ChIP kit) andwas
incubated overnight at 4°C with 2 g of an anti-YY1 antibody (sc-281X;
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Santa Cruz) or IgG, respectively. Immunocomplexes were recovered with
protein A Dynabeads (100-02D; Invitrogen). Finally, DNA was purified
and quantified by qRT-PCR. A list of qRT-PCR primer sequences is pro-
vided in Fig. S5 in the supplemental material.
Immunoprecipitation and Western blot analysis. Total-protein ex-
tracts from cells or tissues were prepared in a buffer containing 20 mM
HEPES (pH 7.9), 125 mM NaCl, 0.3% 3-[(3-cholamidopropyl)-dimeth-
ylammonio]-1-propanesulfonate (CHAPS), 10 mM pyrophosphate, 1
mMEDTA, protease inhibitors, and phosphatase inhibitors. YY1 was im-
munoprecipitated by anti-YY1 antibodies or Flag beads as indicated in the
figure legends, and the interaction with PGC1 was detected by specific
antibodies. All Western blotting with the indicated primary antibodies
was performed by overnight incubation at 4°C.
Transient-transfection and luciferase reporter assays. Transient
transfection was performed in HEK-293 cells using Polyfect (Qiagen) at a
DNA/Polyfect ratio of 1:2. The cell culture medium was changed after 12
h, and rapamycinwas added (20 nM). Cells were lysedwith Reporter Lysis
buffer (Promega) 36 h after transfection, and luciferase assays were per-
formed with the Dual-Glo luciferase assay system (Promega).
GSEA. Gene expression microarrays of total RNA from the solei of
6-month-old YY1mKOmice or wild-type littermates were performed by
the Microarray Core at the Dana-Farber Cancer Institute using an Af-
fymetrix GeneChip Mouse Genome 430A 2.0 array. CEL files were pro-
cessed with the Expression File Creator module from Gene Pattern (http:
//genepattern.broadinstitute.org) using the default parameters, and the
output file was used as input for gene set enrichment analysis (GSEA)
(37). We ran GSEA, version 2.0, using the default parameters but chang-
ing the permutation type to gene set and using MSIGDB collection C2
(curated gene sets), version 3.0.
Mitochondrial isolation and respirometry. Gastrocnemius muscles
(both legs) were homogenized on ice using a Wheaton glass-to-glass
Dounce homogenizer (30 strokes) in ice-cold mitochondrion isolation
buffer formuscle (9a) (100mMKCl, 50mMmorpholinepropanesulfonic
acid [MOPS], 1 mM EDTA, 5 mM MgSO4, 1 mM ATP [pH 7.4] with
bacterial proteinase from Sigma [P8038] at 0.3 mg/g tissue) after a 5-min
incubation at room temperature. The homogenate was diluted 1/2 in
modified mitochondrion isolation buffer (with 0.2 mM ATP and 0.5%
fatty-acid-free bovine serum albumin [BSA]) and was centrifuged at
600 g for 10 min at 4°C. The pellet was discarded and the supernatant
centrifuged at 10,000 g for 10 min at 4°C. The mitochondrial pellet was
washed once with the modified buffer and once with the mitochondrial
isolation buffer (10 min at 10,000  g for each wash). The pellet was
resuspended in HES buffer (pH 7.4) (5mMHEPES, 1mMEDTA, 0.25M
sucrose) and was kept on ice, and protein was quantified using a bicin-
choninic acid (BCA) assay from Pierce. Respirometry was performed us-
ing the XF24-3 platform from Seahorse Biosciences, as described previ-
ously (21, 33). Briefly, 12.5 g of protein (3 to 6 l) was loaded at the
center of the V7 plate on ice, and 50 l of the substrates (5 mM pyruvate
plus 5 mM malate in mitochondrial assay solution [MAS] [pH 7.4]) and
440l ofMAS (70mMsucrose, 220mMmannitol, 5mMKH2PO4, 5mM
MgCl2, 2 mM HEPES, 1 mM EGTA, and 0.2% BSA [pH 7.4]) were care-
fully added on top. All the chemicals loaded in the Seahorse cartridge
ports were diluted in MAS, and the pH was adjusted to 7.4. State 3 was
induced by 1 mM ADP with 5 mM pyruvate plus 5 mMmalate (port A),
state 4o by 2 M oligomycin (complex V/ATP synthase inhibitor), and
uncoupled respiration by 4Mcarbonyl cyanide p-trifluoromethoxyphe-
nylhydrazone (FCCP). Antimycin A (4 M) was used to control back-
ground, nonmitochondrial respiration. C2C12 myoblasts were grown and
differentiated in a Seahorse plate. Basal respirationwas followed, and then
maximal respiration and nonmitochondrial respiration were measured
by addition of FCCP (3 M) and rotenone (2 M).
BN-PAGE analysis. Native protein lysates for blue native polyacryl-
amide gel electrophoresis (BN-PAGE) analysis were obtained by dissolv-
ing the PBS-washed cell pellet in a buffer containing 1.5 M aminocaproic
acid–2% (wt/vol) lauryl maltoside as described in reference 7. Blue native
sample buffer was added as 1/10 of the final sample volume. For prepara-
tion of samples for SDS-PAGE analysis, the BN sample was diluted 1:1
with SDS sample buffer and was incubated for 30 min at room tempera-
ture. BN-PAGE and in-gel activity assays were performed with 5 to 15%
BN-PAGE gels cast as described previously (7). After protein determina-
tion with the BCA kit (Pierce), gels were loaded with 30 g protein per
lane. Complex I and complex IV in-gel activity assays were performed
with NADH–nitroblue tetrazolium and 3,3=-diaminobenzidine tetrahy-
drochloride, respectively, as described previously (7).
Cross-sectional area measurement. Images of sections stained with
H&Ewere captured on a Leicamicroscope at amagnification of20. The
cross-sectional area was quantified using ImageJ software.
Statistical analysis. Data were analyzed by one-way analysis of vari-
ance (ANOVA), followed by an appropriate post hoc test for comparison
between two groups. Significance was defined as a P value of0.05. Data
are presented throughout as means  standard deviations (SD) unless
otherwise indicated.
Microarray data accession number.Themicroarray data determined
in this study have been deposited in GEO under accession number
GSE39009.
RESULTS
Specific skeletal muscle YY1 deficiency results in a dwarf-like
mouse phenotype. Based on our previous findings in skeletal
muscle cells that mitochondrial gene expression was affected by
the transcription factor YY1 (10), we decided to generate skeletal-
muscle-specific YY1 knockout (YY1mKO) mice to assess the bio-
logical function in vivo. YY1mKO mice had developmental
growth and body weight similar to those of wild-type mice until
approximately 2 months of age (Fig. 1A). At this point, whereas
wild-type mice displayed a progressive normal growth curve,
YY1mKOmice stopped growing and maintained a constant body
weight, resulting in a dwarf-like phenotype (Fig. 1B). Interest-
ingly, with age, YY1mKO mouse body weight started to decline,
and mice exhibited signs of muscular dystrophy, such as curving
of the back or kyphosis (Fig. 1C). MRI analysis showed that these
differences in body weight did not result in any difference in the
ratio between fat and lean mass (Fig. 1D). These changes in body
weight occurred despite a significant increase in food intake in
YY1mKO mice (see Fig. S1 in the supplemental material). These
results indicate that specific expression of YY1 in skeletalmuscle is
required for whole-body postnatal growth and that its deficiency
results in a dwarf-like mouse phenotype.
YY1mKO skeletal muscle exhibits abnormal mitochondrial
morphology and distribution defects resembling mitochon-
drial myopathy. Because YY1 was specifically deleted in skeletal
muscle, we visually inspected this tissue to determine whether any
major abnormality existed. Figure 2A shows that the size of skel-
etal muscle tissue did not change significantly in young YY1mKO
mice relative to that in wild-type mice, and at this resolution, they
were apparently normal. It was noticed, however, that the color of
the skeletal muscle was much paler in YY1mKO mice. This was
particularly striking in the soleus muscle, which is characterized
by a high mitochondrial content and oxidative capacity. Interest-
ingly, this phenotype, which is suggestive of decreased mitochon-
drial mass, is similar to that of skeletal-muscle-specific raptor
knockout (RamKO) mice (4) and opposite that of PGC1 trans-
genic mice (22). Next, we examined the skeletal muscles of
YY1mKO mice by H&E staining. A deficiency of YY1 in the skel-
etal muscle resulted in high numbers of small fibers (Fig. 2B, black
arrowheads), fibers with centralized nuclei (green arrowheads),
and central core-like structures (blue arrowheads). Measurement
YY1 Deﬁciency in Skeletal Muscle
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of fiber cross-sectional areas in YY1mKO mice confirmed that
these mice have a prevalence of small fibers compared to the nor-
mal fiber size distribution in wild-type mice (Fig. 2C). Moreover,
23%of fibers in these animals have centralized nuclei (Fig. 2D). To
assessmitochondrialmorphology, we performed electronmicros-
copy (EM) of skeletal muscle from 6-month-old wild-type and
YY1mKO mice (Fig. 3A). Electron micrographs from YY1mKO
soleus muscle exhibited a very disorganized pattern of mitochon-
drial distribution along the different fibers (Fig. 3, compare panels
a and b [wild type] with panels e and f [YY1mKO]). In addition,
these organelles were more fragmented and contained defec-
tive and poorly formed cristae and intramitochondrial gran-
ules or vacuoles (Fig. 3A, compare panels c and d with panels g
to k). This fragmentation might suggest impairments in the
balance of mitochondrial processes such as fusion and fission.
Furthermore, knockout mice show rod-like structures known
as nemaline bodies, which are masses of anomalous Z-band
material (Fig. 3Al). Consistent with the results from the H&E
staining, YY1mKO muscle fibers have centralized nuclei (Fig.
3Aj), a sign of ongoing muscle regeneration. To determine if
the mitochondrial defects observed in YY1mKO mice corre-
lated with decreased mitochondrial function, we performed
histochemistry on the gastrocnemius muscles of wild-type and
knockout mice using staining assays for mitochondrial activity
enzymes (Fig. 3B). The intensities of both succinate dehydro-
genase (SDH) and cytochrome oxidase (COX) staining were
decreased in knockout mice, suggesting decreased mitochon-
drial energetic activity. The glycogen content as measured by
PAS staining, however, was not affected in YY1mKO mice.
Taken together, these results indicate that YY1 deficiency in
skeletal muscle causes significant aberrations in mitochondrial
morphology and distribution as well as bioenergetic defects
that might resemble some phenotypes associated with mito-
chondrial myopathies and diseases.
Mitochondrial genes encoding central bioenergetic meta-
bolic pathways are downregulated in YY1mKO mouse skeletal
muscle. Based on the facts that YY1 controls mitochondrial gene
expression in cultured skeletal muscle cells (10) and that
YY1mKO mice displayed strong derangements in mitochondria
morphology, we performed genomewide expression profiling on
total RNA isolated from wild-type and YY1mKO soleus muscles.
Consistent with YY1 functioning as a repressor or activator of
gene expression, we identified 978 genes whose expression was
increased and 1,228 genes whose expression was decreased by use
of a 1.5-fold change cutoff. Next, we performed GSEA to investi-
gate if there was an enrichment for a pathway among the regulated
genes in one or the other phenotype. In striking agreement with
our previous work in vitro and the severe mitochondrial pheno-
type observed in the skeletalmuscles of YY1mKOmice, among the
20 most significant gene sets enriched in theWT compared to the
KO phenotype, 17 were associated with mitochondrial oxidative
bioenergetic pathways, 2 were annotated as cancer subclasses—in
which there was enrichment inmitochondrial genes—and 1 was a
peroxisomal pathway (Fig. 4A). Based on our interest in the mi-
tochondrial phenotype, we analyzed inmore detail themitochon-
drial pathways that were suppressed by YY1 deficiency in skeletal
muscle. Among the mitochondrial pathways enriched, we found
(i) oxidative phosphorylation (OXPHOS), (ii) energy metabo-
lism, (iii) branched-chain amino acid catabolism, (iv) fatty acid
oxidation, and (v) pyruvatemetabolism and the tricarboxylic acid
(TCA) cycle (Fig. 4B). In the “Mootha mitochondrial” gene set-
enriched pathway, which contains a total of 370 genes, 166 genes
displayed positive core enrichment (45%). In this list, additional
genes were not clustered in the five mitochondrial pathways
FIG 1 Specific genetic deletion of YY1 in skeletal muscle results in a dwarf phenotype. (A) The body weight of wild-type (WT) or YY1mKOmice (n, 9 to 10) was
monitored for 1 year from the age of 2 months. (B) YY1mKO mice are smaller than wild-type mice (age, 1 year). (C) YY1mKO mice develop kyphosis (age, 1
year). (D) MRI of YY1mKO and wild-type mice (age, 1 year; n 10).
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indicated. For example, mitochondrial ribosomal proteins,
heme biosynthesis, reactive oxygen species (ROS) signaling,
mitochondrial protein import, and mitochondrial fusion were
downregulated in the skeletal muscles of YY1mKO mice. Of
interest, one of the gene sets significantly downregulated in
YY1mKO muscle was “Mootha_PGC,” which contains 305
PGC1 muscle target genes and is enriched in mitochondrial
genes (27). Of the 305 genes upregulated by PGC1, 132 genes
were downregulated in YY1mKO mice in this analysis. Impor-
tantly, specific gene changes measured in genomewide expres-
sion profiling were validated using quantitative real-time PCR.
Figure 5A shows that the expression of genes clustered in the
different mitochondrial pathways identified above was lower in
YY1mKOmice than in wild-type mice. In addition, the expres-
sion of mitochondrial regulators, such as mitochondrial tran-
scription factor A (mTFA), nuclear respiratory factors (NRFs),
and estrogen-related receptor alpha (ERR), but not prolifera-
tor-activated receptor gamma coactivator 1 (PGC1) and
peroxisome proliferator-activated receptor delta (PPAR	), was
decreased in YY1mKO mice.
To determine whether YY1 directly regulated the mitochon-
drial bioenergetic genes, we analyzed the occupancy of this tran-
scription factor at several of these gene promoters. As expected,
based on predicted YY1 binding sites, YY1 was recruited at several
FIG 2 Deficiency of YY1 in skeletal muscle results in morphological mitochondrial defects. (A) Appearance of skeletal muscles of 3-month-old wild-type (WT) and
YY1mKOmice. (Left) Soleusmuscle; (right) the whole calf (gastrocnemius, soleus, and plantarismuscles). Arrowheads indicate the soleus. (B) (Top) Cross sections of
gastrocnemius from6-month-oldmalewild-type (a) or YY1mKO(b and c)mice stainedwithH&E. (Bottom) Longitudinal sections fromwild-type (d) or YY1mKO(e
and f) mice stained with H&E. Black arrowheads indicate small fibers; green arrowheads point to cells with centralized nuclei, and blue arrowheads point to central
core-like structures. (C) Cross-sectional area (CSA) distribution in 6-month-old wild-type or YY1mKO fibers. (D) Percentages of cells with centralized nuclei in
6-month-old wild-type or YY1mKO fibers.
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proximal promoters of nuclear mitochondrial genes in skeletal
muscle as well as in differentiated C2C12 myotubes (Fig. 5B; see
also Fig. S2A in the supplemental material). Taken together, these
results indicate that YY1 is a positive and central regulator of a
large number ofmitochondrial genes involved in bioenergetic ox-
idative function.
YY1mKO skeletal muscle exhibits decreased expression of
mitochondrial proteins and defective mitochondrial respira-
tory activity. To assess whether changes in mitochondrial gene
expression observed in the skeletal muscles of YY1mKO mice
translated into changes in protein levels, we analyzed protein ex-
tracts from gastrocnemius muscles of wild-type and YY1mKO
mice. As shown in Fig. 6A, levels of mitochondrial proteins from
the different respiratory chain complexes were decreased in
YY1mKO skeletal muscle. In particular, proteins in complex I
(Nduf9a and Ndufs3) and in complex IV (Cox5a) were strongly
downregulated in YY1mKO mice. Next, to assess whether these
decreases in mitochondrial proteins resulted in functional defects
in complex activity, we measured the in-gel activities of mito-
chondrial complexes I and IV. Consistent with diminished pro-
tein subunit levels, the activities of complex I and IV were signif-
icantly decreased inYY1mKOskeletalmuscle (Fig. 6B). To further
determine mitochondrial bioenergetic dysfunction in the skeletal
muscles of YY1mKO mice, we isolated mitochondria from gas-
trocnemius muscles and performed oxygen consumption mea-
surements using a Seahorse XF analyzer. Mitochondrial pellet
preparations from YY1mKOmuscles were smaller and paler, sug-
gesting a reduction of the levels of mitochondrial cytochromes
(data not shown). The bioenergetic profile of YY1mKO mito-
chondria showed decreased complex I-driven oxygen consump-
tion rates in all respiratory states (ranging from a 42% to a 73%
decrease relative to the same amount of mitochondrial protein
fromwild-typemice), indicating overall decreased electron trans-
port chain activity (Fig. 6C). Collectively, these data indicate that
YY1 deficiency in skeletal muscle strongly compromises mito-
chondrial bioenergetic capacity.
YY1deficiency in skeletalmuscle causes exercise intolerance.
Defects inmitochondrial oxidative function in skeletal muscle are
FIG 3 (A) Representative electron micrographs of soleus muscles of 6-month-old male wild-type (WT) (a to d) and YY1mKO (e to l) mice. (B) Histochemistry
ofmitochondrial proteins and glycogen. Succinate dehydrogenase (SDH) and cytochrome oxidase (COX) activities were determined, and glycogen stainingwith
periodic acid-Schiff stain (PAS) was performed, on sections of gastrocnemius muscle from 6-month-old male mice.
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a clinical symptom of mitochondrial myopathies and cause im-
portant difficulties for physical exercise (38, 40, 51). Given that
YY1mKOmice displayed severemitochondrial abnormalities and
bioenergetic deficits in skeletal muscle, we investigated whether
the ability to perform exercise was altered in these mice. Three
different types of exercise tests were performedwithwild-type and
YY1mKO mice. In the forced treadmill performance to exhaus-
tion, YY1mKO mice ran an average of 59 min and 1,077.5 m,
compared to 90min and 1,721.5m forwild-typemice (Fig. 7A and
B). Moreover, wild-type mice scored a mean of 2.5 falls from the
treadmill in 10min, whereas YY1mKOmice scored 12.5 (Fig. 7C).
In the voluntary wheel performance, wild-type mice spent ap-
proximately 4 times more time in the wheel than did YY1mKO
mice (Fig. 7D). These experiments suggest that consistent with the
defects in mitochondrial function observed in YY1mKO mice,
these mice are intolerant to exercise, a signature often manifested
in mitochondrial diseases.
Mitochondrial genes are not suppressed by rapamycin in
YY1mKOmice.Wehave reported previously that rapamycin sup-
presses mitochondrial genes in cultured cells and in skeletal mus-
cle inmice (5, 10). It was not clear, however, whether this suppres-
sion required YY1 in vivo. To address this, we treated wild-type
and YY1mKOmicewith rapamycin for 2weeks and analyzed gene
expression in skeletal muscle. As expected, levels of transcripts,
including those of transcriptional regulatory genes, OXPHOS
genes, and fatty acid oxidation genes, were decreased upon rapa-
mycin treatment in wild-type mice (Fig. 8A). All the genes in this
list were downregulated in YY1mKOmice, but importantly, rapa-
mycin did not further decrease the expression of these genes.
Moreover, these effects were cell autonomous, since YY1-depleted
myotubes that were treated with rapamycin followed the same
gene expression pattern (Fig. 8B). In addition, the protein levels of
some of these mitochondrial genes were also reduced by rapamy-
cin in myotubes (see Fig. S2B in the supplemental material). To
test whether the effects of rapamycin occurred throughmTORC1,
we used skeletal-muscle-specific raptor knockout mice (4). Con-
sistent with previous reports, RamKO mice exhibited decreased
mitochondrial gene expression and, like YY1mKOmice, were in-
FIG 4 Mitochondrial metabolic genes are downregulated in YY1mKO skeletal muscle. (A) GSEA of the top 20 pathways downregulated in soleus muscles of
3-month-old YY1mKOmice. Red represents mitochondrial pathways, green represents cancer-related pathways, and blue represents the peroxisomal pathway.
ES, enrichment score; NES, normalized enrichment score; NOM p-val, nominal P value; FDR q-val, probability for false discovery rate; FWER p-val, familywise
error rate. (B) Enrichment plots for representative gene expression sets. The color bar depicts the gene list used in the GSEA ordered by differential gene
expression. Red indicates higher (positively correlated) and blue indicates lower(negatively correlated) signal to noise in WT compared to YY1mKOmice.
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FIG 5 Deficiency of YY1 in skeletal muscle results in decreases in the expression of mitochondrial and transcriptional regulatorymitochondrial genes. (A) Gene
expression was measured by quantitative real-time PCR from soleus muscle RNA extracted from 3 month-old fed mice. (B) ChIP analysis from gastrocnemius
muscles of 3 month-old fed mice. All values are presented as means SD. Four to 10 mice were used. *, P 0.05; **, P 0.01.
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sensitive to the suppressive effects of rapamycin on these genes.
Interestingly, the YY1 mRNA levels were also decreased in these
mice (Fig. 8C). These data indicate that the downregulated mito-
chondrial gene expression caused by mTORC1 inactivation (ei-
ther pharmacologically or genetically) requires the transcription
factor YY1.
mTORC1-dependent phosphorylation of YY1 recruits PGC1
and increases mitochondrial gene expression and bioenergetic
function. We next investigated the mechanisms by which
mTORC1 inactivationmediates the suppression ofmitochondrial
genes through YY1. We have previously determined that the in-
teraction between YY1 and PGC1 is disrupted upon rapamycin
treatment (10). In addition, we recently showed that two YY1 sites
(T30 and S365) are phosphorylated only when mTORC1 is active
(5). To address whether these specific YY1 phosphorylation sites
regulate the mTORC1-dependent interaction with PGC1, we
performed immunoprecipitation analysis using a YY1 mutant al-
lele (YY1-AA) that prevents phosphorylation (T30A S365A) in
C2C12 myotubes and HEK-293 cells. As predicted, wild-type YY1
interacted with PGC1, and rapamycin decreased the strength of
this interaction (Fig. 9A and B). Consistent with the data showing
that mTOR-dependent phosphorylation of these two residues
maintains the interaction between YY1 and PGC1, the YY1-AA
mutant had very weak binding to PGC1 and was insensitive to
rapamycin.
In order to support the notion that mTOR controlled YY1
through phosphorylation at the sites identified, we assessed the
functionality of YY1 alleles in transcriptionally based luciferase
assays using the cytochrome c promoter, which contains binding
sites for YY1. Figure 9C shows that wild-type YY1 increased the
transcriptional activity of the cytochrome c promoter, which was
further enhanced with PGC1 expression. These YY1-dependent
transcriptional activities were suppressed by rapamycin. YY1-AA
had amild repressing effect on the basal activity of the cytochrome
c promoter; nevertheless, the overexpression of YY1-AA blunted
the effects of YY1 and PGC1 activation, consistent with the pos-
sibility that this mutant acts as a dominant negative mutant. In
line with the physical interactions, the effect of YY1-AA was in-
sensitive to rapamycin treatment.
Next, we evaluated these transcriptional effects on endogenous
YY1 and PGC1 target genes using adenoviral infection in differ-
entiated primary skeletal muscle cells. Figure 9D shows that wild-
type YY1 increases the expression of a broad range of mitochon-
drial genes; of note, the expression of other transcriptional
regulators of these genes, including PGC1 and PPAR, was
strongly elevated by YY1. In agreement with the data on interac-
tion with PGC1, overexpression of YY1-AA did not result in
increases in the expression of these genes; in fact, it further down-
regulated basal gene expression, suggesting again that it might act
as a dominant negative mutant on endogenous YY1. These regu-
α
µ
FIG 6 YY1mKO skeletal muscles have lower expression of mitochondrial proteins and lower levels of mitochondrial electron chain respiratory activity. (A)
Western blots of mitochondrial proteins in skeletal muscle. (B) OXPHOS complex activities measured by in gel-activity assays (top) and relative quantification
(bottom). (C) Oxygen consumption rates (OCR) measured from total mitochondrial fractions isolated from wild-type and YY1mKO gastrocnemius muscles.
Bars show average OCR values from 4 to 5 mice per group standard errors of the means. The substrates used were 5 mM pyruvate plus 5 mMmalate. State 3
(OCR associated withmaximal ATP synthesis rates) was induced with 1mMADP. State 4o (proton leak, respiration independent of ATP synthesis) was induced
by 2 M oligomycin (complex V inhibitor). Electron transport chain activity independent of ATP synthesis (uncoupled) was induced by 4 M FCCP.
Nonmitochondrial electron transport OCR (background) were determined by the addition of the complex III inhibitor antimycin A (AA). Asterisks indicate
significant differences (*, P 0.05; **, P 0.01) by an unpaired, two-tailed Student t test.
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latory effects of YY1 alleles were consistent with the recruitment of
wild-type YY1, but not YY1-AA, to the promoter regions of sev-
eral mitochondrial genes (Fig. 10A). Importantly, all these
changes in physical interactions and in gene expression translated
into changes in mitochondrial bioenergetic activities. We again
used the Seahorse technology to assess oxygen consumption in
myotubes infected with the different YY1 alleles. Expression of
wild-type YY1, but not YY1-AA, increased oxygen consumption
rates (Fig. 10B). In fact, both basal respiration andmaximal respi-
ratory capacity were higher than those for the control with wild-
type YY1 but lower with YY1-AA. Taken together, these results
indicate that mTOR-mediated phosphorylation on YY1 directly
controls the expression of mitochondrial regulatory genes and
bioenergetic function.
Finally, based on the robust activation of mitochondrial genes
by PGC1 in skeletal muscle cells, we sought to test the require-
ment of YY1 for PGC1 coactivation of shared target genes. Fig-
ure 10C shows that increases in the expression of PGC1 target
mitochondrial genes were substantially attenuated in myotubes
depleted of YY1 by shRNA, suggesting that YY1 is required for
PGC1 to produce full activation of mitochondrial genes.
DISCUSSION
In this study, we have unraveled the physiological role of YY1 in
skeletal muscle, which is to maintain normal mitochondrial func-
tion and morphology. A deficiency of YY1 in this tissue causes
strong suppression of a large number of mitochondrial genes,
leading to severe mitochondrial abnormalities. YY1 recruits the
transcriptional coactivator PGC1 to increase mitochondrial
gene expression. This recruitment requires mTOR activity-de-
pendent YY1 phosphorylation, which promotes the interaction
between YY1 and PGC1. Overall, these results support a pivotal
function of YY1 in maintaining mitochondrial structure and
function and provide themolecular basis of how YY1 inactivation
results in a phenotype resembling mitochondrial myopathies.
The transcription factor YY1 can function as an activator or
repressor of gene transcription involved in different cellular pro-
cesses, but the specific mechanisms underlying this dual function
are unclear (6, 15, 24, 39). In repression, YY1 is associated with
histone deacetylase (HDAC) corepressor complexes, but the se-
lective recruitment to promoters has not been elucidated (42, 50).
In Drosophila, the YY1 homolog called Pleiohomeotic is a Poly-
combprotein found in complexes involved in gene repression and
silencing (2, 45). Of several Polycomb proteins in mammals, only
Pc2 (part of the PRC1 complex) (17) associates with YY1 under
conditions ofmTOR inactivation, and this interaction depends on
the two mTOR-dependent phosphorylation sites T30 and S365
(5). When YY1 functions as an activator, it recruits coactivators
such as p300 and INO80 (3, 6), but how they selectively bind to
promoters to activate YY1 transcriptional function is unknown.
Within the context of mitochondrial gene expression, we show
here that YY1 activation is assigned to recruitment of the PGC1
FIG 7 YY1mKOmice exhibit exercise intolerance. (A and B) Six-month-oldmale wild-type and YY1mKOmice were subjected to forced treadmill performance
until exhaustion, and time (A) and distance (B) were recorded. (C) Number of stops/falls from the treadmill. (D) Voluntary wheel performance. Five to 13mice
were tested. *, P 0.01.
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transcriptional coactivator, which, in contrast to Pc2, is recruited
to YY1whenmTOR is active. Therefore, these datamight explain,
at least in part, promoter-specific YY1 activation or repression
function.
Taken together, the data we present here and our recent data
showing that YY1 controls insulin/insulin growth factor (IGF)
signaling genes (5) indicate that YY1 regulates two major meta-
bolic pathways: insulin/IGF signaling and mitochondrial func-
tion. It is interesting, however, that despite impaired mitochon-
drial oxidative function, hyperactivation of insulin/IGF signaling
in YY1mKO mice is sufficient to increase insulin sensitivity. In
fact, contrary to the prediction that mitochondrial defects would
exacerbate insulin resistance, YY1mKOmice are insulin sensitive
due to increases in insulin/IGF signaling, suggesting that hyperac-
tivation of this pathway can override the mitochondrial dysfunc-
tion in these mice.
YY1 forms part of a group of transcription factors that control
many mitochondrial genes, as illustrated by the gene set enrich-
α α
α α
α α
FIG8 Rapamycin does not suppressmitochondrial genes in YY1mKOorRamKOmice. (A) Six-month-oldmalewild-type andYY1mKOmicewere treatedwith
a vehicle or 2.5mg/kg rapamycin for 14 days. Gene expression wasmeasured by quantitative real-time PCR from soleus RNA extracted from fedmice. (B) C2C12
myotubes were infected with control scrambled shRNA (shScr) or shYY1 for 48 h, and gene expression was measured by quantitative real-time PCR. (C)
Three-month-oldmale wild-type or RamKOmice were treated with a vehicle or 2.5mg/kg rapamycin for 14 days. Gene expressionwasmeasured by quantitative
real-time PCR from soleus RNA extracted from fed mice. All values are presented as means SD. Four to 10 mice were used. *, P 0.05; **, P 0.01.
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ment analysis performed in these studies. Thus, nuclear YY1
maintains the activation of mitochondrial genes encoding pro-
teins involved in different mitochondrial processes, from bioen-
ergetics to protein import, that are necessary for the formation of
proper structural and functional organelles. Indeed, YY1 binding
sites are present in a large number of mitochondrial genes where
YY1 is recruited (Fig. 5B) (13), and part of this activation is due to
PGC1, which is both induced and coactivated by YY1. Neverthe-
less, in ourmicroarray analysis, we identified somemitochondrial
respiratory genes that are not regulated by YY1 (see Fig. S3 in the
supplemental material), suggesting a specific rather than a general
regulation of this pathway. The global effects of YY1 onmitochon-
drial gene expression are part of a complex transcriptional net-
work with synergies among the different components. This is ex-
emplified by the interaction presented here between YY1 and
PGC1, which would impact additional transcription factors,
such as NRFs and ERRs, that control mitochondrial gene expres-
sion and are coactivated by PGC1 (18, 26, 36, 48). An important
question is under what regulatory conditions YY1 operates to in-
crease mitochondrial gene expression. Our results indicate that in
the context ofmTORactivation, YY1 remained bound to the tran-
scriptional coactivator PGC1 and that these genes were acti-
vated. It is conceivable, however, that other regulatory pathways
impinge on YY1 without changes in mTOR activity. For example,
increases in PGC1 levels that occur through activation of differ-
ent signaling pathways involving cyclic AMP (cAMP) or calcium
signaling (30, 47) could allow more binding between YY1 and
PGC1. Alternatively, although mTOR activity controls YY1 T30
and S365 phosphorylation, other, additional kinases and/or phos-
phatases could regulate the phosphorylation of these residues on
YY1 independently of mTOR.
At this point, it is not clear howmuch of the effect of PGC1 on
mitochondrial genes is mediated by YY1. In an attempt to answer
this question, wemeasured the effect of PGC1 onmitochondrial
genes in C2C12 myotubes that were depleted of YY1 by shRNA
(Fig. 10C). YY1 reduction decreased the effects of PGC1 2-fold.
It is difficult to interpret these data, because YY1 is depleted only
to 50% by shRNA. However, it is likely that other transcription
factors, including NRFs and ERR, could work independently of
YY1 and thus explain the residual PGC1 effects on mitochon-
drial genes in YY1 shRNA cells.
A deficiency of YY1 in skeletal muscle causes impaired postna-
α
α
α α 
FIG 9 mTORC1-dependent phosphorylation of YY1 recruits PGC1 and increases mitochondrial gene expression and bioenergetic function. (A) Coimmu-
noprecipitation of Flag-labeled YY1 and hemagglutinin (HA)-labeled PGC1 in C2C12 myotubes treated with a vehicle or 20 nM rapamycin for 2 h. IP,
immunoprecipitation. (B) Coimmunoprecipitation of Flag-YY1 and HA-PGC1 in HEK-293 cells treated with a vehicle or 20 nM rapamycin for 2 h. (C)
Luciferase assay in HEK-293 cells transfected with a cytochrome c luciferase construct and the indicated proteins. Rapamycin (20 nM) was added as indicated 24
h before cell lysis. Data are expressed as fold activation and were normalized to the level of expression in an empty-vector-transfected control. a, significant
difference (P 0.01) between the control and the overexpressed plasmid; b, significant difference (P 0.01) between the vehicle and rapamycin; **, P 0.01.
(D) Primary muscle myotubes were infected with green fluorescent protein (GFP), Flag-YY1, or Flag-YY1-AA for 48 h, and gene expression was measured by
quantitative real-time PCR. All values are presented as means SD. Four to 10 mice were used. **, P 0.01; ***, P 0.001.
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tal growth and a dwarf phenotype. Themechanisms bywhich YY1
in this tissue is necessary to promote normal growth are unknown,
but the findings suggest that YY1 might control the action of sys-
temic factors, such as growth hormone, necessary for whole-body
growth. Of interest, in some types of mitochondrial myopathies,
patients often present a short stature, suggesting that mitochon-
drial dysregulation in skeletal muscle might be an underlying
cause of defective postnatal growth (46). Nevertheless, since YY1
also controls genes involved in the cell cycle and translation, we
could not exclude the possibility that the defective growth is due to
a decrease in these pathways. However, our results show that cell
cycle genes and protein translation are increased in YY1mKO
mice (see Fig. S4 in the supplemental material).
In agreement with mitochondrial dysfunction, a deficiency of
YY1 in skeletal muscle causes exercise intolerance. The positive
regulatory roles of PGC1 and mTORC1 in exercise are well es-
tablished (4, 22), and we show here that YY1, which interacts with
mTORC1 and PGC1 (Fig. 9A and B) (10), is also necessary to
maintain full exercise capabilities. Exercise intolerance in
YY1mKO mice is also consistent with the profound mitochon-
drial defects observed in different genetic models of mTOR and
PGC1 in skeletal muscle (4, 22, 32). In this sense, regulation of
mTOR during exercise might maintain mitochondrial function
throughYY1/PGC1 transcriptional activity. It is also conceivable
that loss of YY1 in skeletal muscle affects other components of the
muscle fiber involved in contraction andmovement. For example,
we observed that several genes associatedwith skeletalmuscle dys-
trophy are affected in YY1mKOmice, and at older ages, thesemice
developed kyphosis. These signs of dystrophy, however, are not as
severe as those described in skeletal-muscle-specific mTOR or
raptor KO mice (4, 32).
In addition, YY1 deficiency resembles several models of mi-
tochondrial myopathies and diseases, a finding mechanistically
supported by the direct transcriptional control of YY1 at the
promoters of a large number of mitochondrial genes, some of
them mutated in these diseases. Nevertheless, at present we
cannot exclude the possibility that other pathways besides mi-
tochondria contribute to the exercise phenotype in YY1mKO
mice.
In summary, our studies reveal a key role of the transcription
factor YY1 in maintaining the expression of a large number of
mitochondrial genes in skeletal muscle that are responsible for
retaining mitochondrial structure and function. A deficiency of
YY1 in skeletal muscle results in reduced exercise capability and
the appearance of signs of mitochondrial myopathy. Finally, these
results would predict the possibility that increases in YY1 activity,
like increases in mTORC1 and PGC1 activities, might improve
skeletal muscle function and help to prevent several types of mi-
tochondrial myopathies.
ααααα
α
FIG10 YY1 binds to nuclearmitochondrial genes and increases oxygen consumption in culturedmuscle cells. (A)ChIPwas performed inC2C12myotubes using
antibodies specific for Flag or IgG. All values are presented asmeans standard errors of themeans. Fourmicewere used. *,P 0.05; **,P 0.01; ***,P 0.001.
Cyt c, cytochrome c. (B) Oxygen consumption rates (OCR) in C2C12 myotubes infected with green fluorescent protein (GFP), Flag-YY1, or Flag-YY1-AA.
Mitoch, mitochondrial. (C) C2C12 myotubes were infected with either shScrambled or shYY1 and with GFP or PGC1 for 72 h, and gene expression was
measured by quantitative real-time PCR. All values are presented as means SD. Four to 10 mice were used. *, P 0.05; **, P 0.01.
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